Weekly Trend Brief2026 W46
GLP-1 Eye Side Effect Warnings Spread, Controversy From Day One of Overseas Imports
This was a week where safety warnings and price controversies around GLP-1 obesity drugs broke out at the same time. The Ministry of Food and Drug Safety (MFDS) officially issued wording about vision damage risk, and on the same day, personal imports of overseas prescription drugs took effect, stirring up controversy over price gaps and safety management blind spots. Meanwhile, in the protein and blood-sugar-management health functional food market, competition among large companies for new products intensified.
01Top 5 this week
Links go to the original articles; titles are in their original language.
02By topic
- GLP-1
- Warnings about vision damage (optic neuropathy) from GLP-1 drugs were officially issued by both the MFDS and the FDA, and as personal imports of overseas prescription drugs took effect, the 'Sushi-Jaro' trend of prescription trips to Japan and price controversy grew. Reports also continued to stress concerns about muscle loss and the importance of protein intake.
- Protein
- Competition between major companies and new brands is intensifying in the protein drink and shake market. Pulmuone's new product, Vazio's No. 1 ranking at Olive Young, and Take-Fit's sales growth stood out, while globally, diversification continued with clear protein and protein coffee formats.
- Supplements & brands
- Alongside new blood-sugar-management shake launches, a McKinsey survey found that consumers are demanding stronger evidence for health functional foods. Some products were recalled after failing quality inspections.
- Regulation & safety
- The MFDS distributed a safety letter on vision damage risk covering the entire GLP-1 class, and as the personal import system for overseas prescription drugs took effect, the National Assembly pointed out gaps in follow-up management. There was also news of a crackdown on false patent claims for health foods.
03Glossary
- Optic neuropathy
- A condition where problems with blood flow to the eye can damage vision.
- Semaglutide (Wegovy)
- An ingredient that reduces appetite to help with weight loss, sold under the brand name Wegovy.
- Tirzepatide (Mounjaro)
- An obesity/diabetes treatment ingredient that works similarly to semaglutide.
- Halo effect
- A term referring to consumers who change their eating habits like GLP-1 users even though they don't use the drugs.
- Clear protein
- A protein drink made in a clear form rather than a cloudy, milk-like one.
04What to watch next week
- It's worth watching how the MFDS's review of label changes for the GLP-1 class (reflecting possible blindness risk) gets finalized after next week.
- It's worth watching whether the National Assembly and MFDS take further supplementary measures regarding the personal import system for overseas prescription drugs.
- It's worth watching whether demand for 'Sushi-Jaro' prescription trips to Japan keeps rising, and how hospitals in Japan respond.
